Blair Leavitt Publications

  • Moss, DJH, Pardiñas, AF, Langbehn, D, Lo, K, Leavitt, BR, Roos, R et al.. Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurol. 2017; :. doi: 10.1016/S1474-4422(17)30161-8. PubMed PMID:28642124 .
  • Byrne, LM, Rodrigues, FB, Blennow, K, Durr, A, Leavitt, BR, Roos, RAC et al.. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. Lancet Neurol. 2017; :. doi: 10.1016/S1474-4422(17)30124-2. PubMed PMID:28601473 .
  • Quinti, L, Dayalan Naidu, S, Träger, U, Chen, X, Kegel-Gleason, K, Llères, D et al.. KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proc. Natl. Acad. Sci. U.S.A. 2017;114 (23):E4676-E4685. doi: 10.1073/pnas.1614943114. PubMed PMID:28533375 PubMed Central PMC5468652.
  • McColgan, P, Seunarine, KK, Gregory, S, Razi, A, Papoutsi, M, Long, JD et al.. Topological length of white matter connections predicts their rate of atrophy in premanifest Huntington's disease. JCI Insight. 2017;2 (8):. doi: 10.1172/jci.insight.92641. PubMed PMID:28422761 PubMed Central PMC5396531.
  • Park, KHJ, Franciosi, S, Parrant, K, Lu, G, Leavitt, BR. p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease. Neuroscience. 2017;352 :79-87. doi: 10.1016/j.neuroscience.2017.03.051. PubMed PMID:28391013 .
  • Gregory, S, Long, JD, Klöppel, S, Razi, A, Scheller, E, Minkova, L et al.. Operationalizing compensation over time in neurodegenerative disease. Brain. 2017;140 (4):1158-1165. doi: 10.1093/brain/awx022. PubMed PMID:28334888 PubMed Central PMC5382953.
  • McColgan, P, Razi, A, Gregory, S, Seunarine, KK, Durr, A, A C Roos, R et al.. Structural and functional brain network correlates of depressive symptoms in premanifest Huntington's disease. Hum Brain Mapp. 2017;38 (6):2819-2829. doi: 10.1002/hbm.23527. PubMed PMID:28294457 PubMed Central PMC5434856.
  • McColgan, P, Gregory, S, Razi, A, Seunarine, KK, Gargouri, F, Durr, A et al.. White matter predicts functional connectivity in premanifest Huntington's disease. Ann Clin Transl Neurol. 2017;4 (2):106-118. doi: 10.1002/acn3.384. PubMed PMID:28168210 PubMed Central PMC5288460.
  • Disatnik, MH, Joshi, AU, Saw, NL, Shamloo, M, Leavitt, BR, Qi, X et al.. Potential biomarkers to follow the progression and treatment response of Huntington's disease. J. Exp. Med. 2016;213 (12):2655-2669. doi: 10.1084/jem.20160776. PubMed PMID:27821553 PubMed Central PMC5110026.
  • Orth, M, Gregory, S, Scahill, RI, Mayer, IS, Minkova, L, Klöppel, S et al.. Natural variation in sensory-motor white matter organization influences manifestations of Huntington's disease. Hum Brain Mapp. 2016;37 (12):4615-4628. doi: 10.1002/hbm.23332. PubMed PMID:27477323 .
  • Rodrigues, FB, Byrne, L, McColgan, P, Robertson, N, Tabrizi, SJ, Leavitt, BR et al.. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease. J. Neurochem. 2016;139 (1):22-5. doi: 10.1111/jnc.13719. PubMed PMID:27344050 PubMed Central PMC5053298.
  • Labuschagne, I, Cassidy, AM, Scahill, RI, Johnson, EB, Rees, E, O'Regan, A et al.. Visuospatial Processing Deficits Linked to Posterior Brain Regions in Premanifest and Early Stage Huntington's Disease. J Int Neuropsychol Soc. 2016;22 (6):595-608. doi: 10.1017/S1355617716000321. PubMed PMID:27211109 .
  • Connolly, C, Magnusson-Lind, A, Lu, G, Wagner, PK, Southwell, AL, Hayden, MR et al.. Enhanced immune response to MMP3 stimulation in microglia expressing mutant huntingtin. Neuroscience. 2016;325 :74-88. doi: 10.1016/j.neuroscience.2016.03.031. PubMed PMID:27033979 .
  • De Souza, RA, Islam, SA, McEwen, LM, Mathelier, A, Hill, A, Mah, SM et al.. DNA methylation profiling in human Huntington's disease brain. Hum. Mol. Genet. 2016;25 (10):2013-2030. doi: 10.1093/hmg/ddw076. PubMed PMID:26953320 .
  • Petkau, TL, Hill, A, Leavitt, BR. Core neuropathological abnormalities in progranulin-deficient mice are penetrant on multiple genetic backgrounds. Neuroscience. 2016;315 :175-95. doi: 10.1016/j.neuroscience.2015.12.006. PubMed PMID:26701296 .
  • Minkova, L, Scheller, E, Peter, J, Abdulkadir, A, Kaller, CP, Roos, RA et al.. Detection of Motor Changes in Huntington's Disease Using Dynamic Causal Modeling. Front Hum Neurosci. 2015;9 :634. doi: 10.3389/fnhum.2015.00634. PubMed PMID:26635585 PubMed Central PMC4658414.
  • Klöppel, S, Gregory, S, Scheller, E, Minkova, L, Razi, A, Durr, A et al.. Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine. 2015;2 (10):1420-9. doi: 10.1016/j.ebiom.2015.08.002. PubMed PMID:26629536 PubMed Central PMC4634199.
  • Johnson, EB, Rees, EM, Labuschagne, I, Durr, A, Leavitt, BR, Roos, RA et al.. The impact of occipital lobe cortical thickness on cognitive task performance: An investigation in Huntington's Disease. Neuropsychologia. 2015;79 (Pt A):138-46. doi: 10.1016/j.neuropsychologia.2015.10.033. PubMed PMID:26519555 .
  • Minkova, L, Eickhoff, SB, Abdulkadir, A, Kaller, CP, Peter, J, Scheller, E et al.. Large-scale brain network abnormalities in Huntington's disease revealed by structural covariance. Hum Brain Mapp. 2016;37 (1):67-80. doi: 10.1002/hbm.23014. PubMed PMID:26453902 .
  • Wagner, L, Wolf, R, Zeitschel, U, Rossner, S, Petersén, Å, Leavitt, BR et al.. Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery. J. Neurochem. 2015;135 (5):1019-37. doi: 10.1111/jnc.13378. PubMed PMID:26442809 .
  • Mazarei, G, Leavitt, BR. Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease. J Huntingtons Dis. 2015;4 (2):109-18. doi: 10.3233/JHD-159003. PubMed PMID:26397892 PubMed Central PMC4923717.
  • Howard, AK, Krishnamoorthy, A, Leavitt, BR, Raymond, LA, Weissman, CR. Treatment of Huntington Disease and Comorbid Trichotillomania With Aripiprazole. J Neuropsychiatry Clin Neurosci. 2015;27 (3):e211-2. doi: 10.1176/appi.neuropsych.14090232. PubMed PMID:26222972 .
  • Southwell, AL, Smith, SE, Davis, TR, Caron, NS, Villanueva, EB, Xie, Y et al.. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep. 2015;5 :12166. doi: 10.1038/srep12166. PubMed PMID:26174131 PubMed Central PMC4502413.
  • Jan, A, Karasinska, JM, Kang, MH, de Haan, W, Ruddle, P, Kaur, A et al.. Direct intracerebral delivery of a miR-33 antisense oligonucleotide into mouse brain increases brain ABCA1 expression. [Corrected]. Neurosci. Lett. 2015;598 :66-72. doi: 10.1016/j.neulet.2015.05.007. PubMed PMID:25957561 .
  • Bečanović, K, Nørremølle, A, Neal, SJ, Kay, C, Collins, JA, Arenillas, D et al.. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease. Nat. Neurosci. 2015;18 (6):807-16. doi: 10.1038/nn.4014. PubMed PMID:25938884 .
  • Wild, EJ, Boggio, R, Langbehn, D, Robertson, N, Haider, S, Miller, JR et al.. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J. Clin. Invest. 2015;125 (5):1979-86. doi: 10.1172/JCI80743. PubMed PMID:25844897 PubMed Central PMC4463213.
  • Callaghan, J, Stopford, C, Arran, N, Boisse, MF, Coleman, A, Santos, RD et al.. Reliability and factor structure of the Short Problem Behaviors Assessment for Huntington's disease (PBA-s) in the TRACK-HD and REGISTRY studies. J Neuropsychiatry Clin Neurosci. 2015;27 (1):59-64. doi: 10.1176/appi.neuropsych.13070169. PubMed PMID:25716488 .
  • Sturrock, A, Laule, C, Wyper, K, Milner, RA, Decolongon, J, Dar Santos, R et al.. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Mov. Disord. 2015;30 (3):393-401. doi: 10.1002/mds.26118. PubMed PMID:25690257 .
  • Bates, GP, Dorsey, R, Gusella, JF, Hayden, MR, Kay, C, Leavitt, BR et al.. Huntington disease. Nat Rev Dis Primers. 2015;1 :15005. doi: 10.1038/nrdp.2015.5. PubMed PMID:27188817 .
  • Träger, U, Andre, R, Magnusson-Lind, A, Miller, JR, Connolly, C, Weiss, A et al.. Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiol. Dis. 2015;73 :388-98. doi: 10.1016/j.nbd.2014.10.012. PubMed PMID:25447230 PubMed Central PMC4262574.
  • De Souza, RA, Leavitt, BR. Neurobiology of Huntington's Disease. Curr Top Behav Neurosci. 2015;22 :81-100. doi: 10.1007/7854_2014_353. PubMed PMID:25205327 .
  • Reilmann, R, Leavitt, BR, Ross, CA. Huntington's disease: a field on the move. Introduction. Mov. Disord. 2014;29 (11):1333-4. doi: 10.1002/mds.26017. PubMed PMID:25164859 .
  • Reilmann, R, Leavitt, BR, Ross, CA. Diagnostic criteria for Huntington's disease based on natural history. Mov. Disord. 2014;29 (11):1335-41. doi: 10.1002/mds.26011. PubMed PMID:25164527 .
  • Jones, R, Stout, JC, Labuschagne, I, Say, M, Justo, D, Coleman, A et al.. The potential of composite cognitive scores for tracking progression in Huntington's disease. J Huntingtons Dis. 2014;3 (2):197-207. doi: 10.3233/JHD-140101. PubMed PMID:25062862 .
  • Plecash, AR, Leavitt, BR. Aquatherapy for neurodegenerative disorders. J Huntingtons Dis. 2014;3 (1):5-11. doi: 10.3233/JHD-140010. PubMed PMID:25062761 .
  • Petkau, TL, Leavitt, BR. Progranulin in neurodegenerative disease. Trends Neurosci. 2014;37 (7):388-98. doi: 10.1016/j.tins.2014.04.003. PubMed PMID:24800652 .
  • Wang, SP, Wu, JW, Bourdages, H, Lefebvre, JF, Casavant, S, Leavitt, BR et al.. The catalytic function of hormone-sensitive lipase is essential for fertility in male mice. Endocrinology. 2014;155 (8):3047-53. doi: 10.1210/en.2014-1031. PubMed PMID:24797631 .
  • Kostro, D, Abdulkadir, A, Durr, A, Roos, R, Leavitt, BR, Johnson, H et al.. Correction of inter-scanner and within-subject variance in structural MRI based automated diagnosing. Neuroimage. 2014;98 :405-15. doi: 10.1016/j.neuroimage.2014.04.057. PubMed PMID:24791746 .
  • Muller, M, Leavitt, BR. Iron dysregulation in Huntington's disease. J. Neurochem. 2014;130 (3):328-50. doi: 10.1111/jnc.12739. PubMed PMID:24717009 .
  • Ross, CA, Aylward, EH, Wild, EJ, Langbehn, DR, Long, JD, Warner, JH et al.. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10 (4):204-16. doi: 10.1038/nrneurol.2014.24. PubMed PMID:24614516 .
  • Park, KH, Franciosi, S, Leavitt, BR. Postnatal muscle modification by myogenic factors modulates neuropathology and survival in an ALS mouse model. Nat Commun. 2013;4 :2906. doi: 10.1038/ncomms3906. PubMed PMID:24346342 PubMed Central PMC4965267.
  • Franciosi, S, Shim, Y, Lau, M, Hayden, MR, Leavitt, BR. A systematic review and meta-analysis of clinical variables used in Huntington disease research. Mov. Disord. 2013;28 (14):1987-94. doi: 10.1002/mds.25663. PubMed PMID:24142393 .
  • Saft, C, Leavitt, BR, Epplen, JT. Clinical utility gene card for: Huntington's disease. Eur. J. Hum. Genet. 2014;22 (5):. doi: 10.1038/ejhg.2013.206. PubMed PMID:24105375 PubMed Central PMC3992568.
  • Ehrnhoefer, DE, Skotte, NH, Ladha, S, Nguyen, YT, Qiu, X, Deng, Y et al.. p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Hum. Mol. Genet. 2014;23 (3):717-29. doi: 10.1093/hmg/ddt458. PubMed PMID:24070868 .
  • Mazarei, G, Budac, DP, Lu, G, Lee, H, Möller, T, Leavitt, BR et al.. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain. Exp. Neurol. 2013;249 :144-8. doi: 10.1016/j.expneurol.2013.08.007. PubMed PMID:23994717 .
  • Zhu, S, Tai, C, Petkau, TL, Zhang, S, Liao, C, Dong, Z et al.. Progranulin promotes activation of microglia/macrophage after pilocarpine-induced status epilepticus. Brain Res. 2013;1530 :54-65. doi: 10.1016/j.brainres.2013.07.023. PubMed PMID:23887054 .
  • Mazarei, G, Budac, DP, Lu, G, Adomat, H, Tomlinson Guns, ES, Möller, T et al.. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease. J. Neurochem. 2013;127 (6):852-67. doi: 10.1111/jnc.12350. PubMed PMID:23786539 .
  • Petkau, TL, Zhu, S, Lu, G, Fernando, S, Cynader, M, Leavitt, BR et al.. Sensitivity to neurotoxic stress is not increased in progranulin-deficient mice. Neurobiol. Aging. 2013;34 (11):2548-50. doi: 10.1016/j.neurobiolaging.2013.04.019. PubMed PMID:23702345 .
  • Tabrizi, SJ, Scahill, RI, Owen, G, Durr, A, Leavitt, BR, Roos, RA et al.. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 2013;12 (7):637-49. doi: 10.1016/S1474-4422(13)70088-7. PubMed PMID:23664844 .
  • Borowsky, B, Warner, J, Leavitt, BR, Tabrizi, SJ, Roos, RA, Durr, A et al.. 8OHdG is not a biomarker for Huntington disease state or progression. Neurology. 2013;80 (21):1934-41. doi: 10.1212/WNL.0b013e318293e1a1. PubMed PMID:23616162 PubMed Central PMC3716347.
  • Read, J, Jones, R, Owen, G, Leavitt, BR, Coleman, A, Roos, RA et al.. Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners. J Huntingtons Dis. 2013;2 (2):159-75. doi: 10.3233/JHD-130051. PubMed PMID:25063513 .
  • Crawford, HE, Hobbs, NZ, Keogh, R, Langbehn, DR, Frost, C, Johnson, H et al.. Corpus callosal atrophy in premanifest and early Huntington's disease. J Huntingtons Dis. 2013;2 (4):517-26. doi: 10.3233/JHD-130077. PubMed PMID:25062736 .
  • Leavitt, BR, Thompson, LM. We are pleased to introduce this next volume of the Journal of Huntington's Disease. Introduction. J Huntingtons Dis. 2013;2 (1):1. doi: 10.3233/JHD-130003. PubMed PMID:25057106 .
  • Boxer, AL, Gold, M, Huey, E, Hu, WT, Rosen, H, Kramer, J et al.. The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier). Alzheimers Dement. 2013;9 (2):189-98. doi: 10.1016/j.jalz.2012.03.003. PubMed PMID:23062850 PubMed Central PMC3562382.
  • Boxer, AL, Gold, M, Huey, E, Gao, FB, Burton, EA, Chow, T et al.. Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development. Alzheimers Dement. 2013;9 (2):176-88. doi: 10.1016/j.jalz.2012.03.002. PubMed PMID:23043900 PubMed Central PMC3542408.
  • Stout, JC, Jones, R, Labuschagne, I, O'Regan, AM, Say, MJ, Dumas, EM et al.. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J. Neurol. Neurosurg. Psychiatr. 2012;83 (7):687-94. doi: 10.1136/jnnp-2011-301940. PubMed PMID:22566599 PubMed Central PMC3368487.
  • Tang, B, Becanovic, K, Desplats, PA, Spencer, B, Hill, AM, Connolly, C et al.. Forkhead box protein p1 is a transcriptional repressor of immune signaling in the CNS: implications for transcriptional dysregulation in Huntington disease. Hum. Mol. Genet. 2012;21 (14):3097-111. doi: 10.1093/hmg/dds132. PubMed PMID:22492998 PubMed Central PMC3384380.
  • Long, JD, Matson, WR, Juhl, AR, Leavitt, BR, Paulsen, JS, PREDICT-HD Investigators and Coordinators of the Huntington Study Group et al.. 8OHdG as a marker for Huntington disease progression. Neurobiol. Dis. 2012;46 (3):625-34. doi: 10.1016/j.nbd.2012.02.012. PubMed PMID:22414782 PubMed Central PMC3784019.
  • Dumas, EM, Say, MJ, Jones, R, Labuschagne, I, O'Regan, AM, Hart, EP et al.. Visual Working Memory Impairment in Premanifest Gene-Carriers and Early Huntington's Disease. J Huntingtons Dis. 2012;1 (1):97-106. doi: 10.3233/JHD-2012-120010. PubMed PMID:25063192 .
  • Leavitt, BR, Thompson, LM. Journal of Huntington's Disease. J Huntingtons Dis. 2012;1 (1):1. doi: 10.3233/JHD-2012-120001. PubMed PMID:25056612 .
  • Park, KH, Lu, G, Fan, J, Raymond, LA, Leavitt, BR. Decreasing Levels of the cdk5 Activators, p25 and p35, Reduces Excitotoxicity in Striatal Neurons. J Huntingtons Dis. 2012;1 (1):89-96. doi: 10.3233/JHD-2012-129000. PubMed PMID:24353748 PubMed Central PMC3864911.
  • Scahill, RI, Hobbs, NZ, Say, MJ, Bechtel, N, Henley, SM, Hyare, H et al.. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp. 2013;34 (3):519-29. doi: 10.1002/hbm.21449. PubMed PMID:22102212 .
  • Petkau, TL, Neal, SJ, Milnerwood, A, Mew, A, Hill, AM, Orban, P et al.. Synaptic dysfunction in progranulin-deficient mice. Neurobiol. Dis. 2012;45 (2):711-22. doi: 10.1016/j.nbd.2011.10.016. PubMed PMID:22062772 .
  • Franciosi, S, Ryu, JK, Shim, Y, Hill, A, Connolly, C, Hayden, MR et al.. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2012;45 (1):438-49. doi: 10.1016/j.nbd.2011.09.003. PubMed PMID:21946335 .
  • Sivananthan, SN, Leavitt, BR. Cystamine and ethyl-eicosapentaenoic acid treatment fail to prevent malonate-induced striatal toxicity in mice. Neurobiol. Aging. 2011;32 (12):2326.e1-4. doi: 10.1016/j.neurobiolaging.2011.05.020. PubMed PMID:21741126 .
  • Fotovati, A, Abu-Ali, S, Wang, PS, Deleyrolle, LP, Lee, C, Triscott, J et al.. YB-1 bridges neural stem cells and brain tumor-initiating cells via its roles in differentiation and cell growth. Cancer Res. 2011;71 (16):5569-78. doi: 10.1158/0008-5472.CAN-10-2805. PubMed PMID:21730024 .
  • Weir, DW, Sturrock, A, Leavitt, BR. Development of biomarkers for Huntington's disease. Lancet Neurol. 2011;10 (6):573-90. doi: 10.1016/S1474-4422(11)70070-9. PubMed PMID:21601164 .
  • Hobbs, NZ, Pedrick, AV, Say, MJ, Frost, C, Dar Santos, R, Coleman, A et al.. The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Mov. Disord. 2011;26 (9):1684-90. doi: 10.1002/mds.23747. PubMed PMID:21557312 .
  • Tabrizi, SJ, Scahill, RI, Durr, A, Roos, RA, Leavitt, BR, Jones, R et al.. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011;10 (1):31-42. doi: 10.1016/S1474-4422(10)70276-3. PubMed PMID:21130037 .
  • Bechtel, N, Scahill, RI, Rosas, HD, Acharya, T, van den Bogaard, SJ, Jauffret, C et al.. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology. 2010;75 (24):2150-60. doi: 10.1212/WNL.0b013e3182020123. PubMed PMID:21068430 PubMed Central PMC3013584.
  • Sturrock, A, Laule, C, Decolongon, J, Dar Santos, R, Coleman, AJ, Creighton, S et al.. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology. 2010;75 (19):1702-10. doi: 10.1212/WNL.0b013e3181fc27e4. PubMed PMID:21060093 PubMed Central PMC3033605.
  • Metzler, M, Gan, L, Mazarei, G, Graham, RK, Liu, L, Bissada, N et al.. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J. Neurosci. 2010;30 (43):14318-29. doi: 10.1523/JNEUROSCI.1589-10.2010. PubMed PMID:20980587 .
  • Sturrock, A, Leavitt, BR. The clinical and genetic features of Huntington disease. J Geriatr Psychiatry Neurol. 2010;23 (4):243-59. doi: 10.1177/0891988710383573. PubMed PMID:20923757 .
  • Petkau, TL, Neal, SJ, Orban, PC, MacDonald, JL, Hill, AM, Lu, G et al.. Progranulin expression in the developing and adult murine brain. J. Comp. Neurol. 2010;518 (19):3931-47. doi: 10.1002/cne.22430. PubMed PMID:20737593 .
  • Pouladi, MA, Xie, Y, Skotte, NH, Ehrnhoefer, DE, Graham, RK, Kim, JE et al.. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum. Mol. Genet. 2010;19 (8):1528-38. doi: 10.1093/hmg/ddq026. PubMed PMID:20097678 PubMed Central PMC2846162.
  • Becanovic, K, Pouladi, MA, Lim, RS, Kuhn, A, Pavlidis, P, Luthi-Carter, R et al.. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Hum. Mol. Genet. 2010;19 (8):1438-52. doi: 10.1093/hmg/ddq018. PubMed PMID:20089533 PubMed Central PMC2846159.
  • Mazarei, G, Neal, SJ, Becanovic, K, Luthi-Carter, R, Simpson, EM, Leavitt, BR et al.. Expression analysis of novel striatal-enriched genes in Huntington disease. Hum. Mol. Genet. 2010;19 (4):609-22. doi: 10.1093/hmg/ddp527. PubMed PMID:19934114 PubMed Central PMC2807369.
  • Tabrizi, SJ, Langbehn, DR, Leavitt, BR, Roos, RA, Durr, A, Craufurd, D et al.. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8 (9):791-801. doi: 10.1016/S1474-4422(09)70170-X. PubMed PMID:19646924 PubMed Central PMC3725974.
  • Yeretssian, G, Doiron, K, Shao, W, Leavitt, BR, Hayden, MR, Nicholson, DW et al.. Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proc. Natl. Acad. Sci. U.S.A. 2009;106 (22):9016-20. doi: 10.1073/pnas.0813362106. PubMed PMID:19447924 PubMed Central PMC2690057.
  • Joshi, PR, Wu, NP, André, VM, Cummings, DM, Cepeda, C, Joyce, JA et al.. Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease. J. Neurosci. 2009;29 (8):2414-27. doi: 10.1523/JNEUROSCI.5687-08.2009. PubMed PMID:19244517 PubMed Central PMC2670193.
  • Graham, RK, Pouladi, MA, Joshi, P, Lu, G, Deng, Y, Wu, NP et al.. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. J. Neurosci. 2009;29 (7):2193-204. doi: 10.1523/JNEUROSCI.5473-08.2009. PubMed PMID:19228972 PubMed Central PMC2729178.
  • Hayden, MR, Leavitt, BR, Yasothan, U, Kirkpatrick, P. Tetrabenazine. Nat Rev Drug Discov. 2009;8 (1):17-8. doi: 10.1038/nrd2784. PubMed PMID:19116624 .
  • Fang, Q, Strand, A, Law, W, Faca, VM, Fitzgibbon, MP, Hamel, N et al.. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol. Cell Proteomics. 2009;8 (3):451-66. doi: 10.1074/mcp.M800231-MCP200. PubMed PMID:18984577 PubMed Central PMC2649809.
  • Orban, P, Devon, RS, Hayden, MR, Leavitt, BR. Chapter 15 Juvenile amyotrophic lateral sclerosis. Handb Clin Neurol. 2007;82 :301-12. doi: 10.1016/S0072-9752(07)80018-2. PubMed PMID:18808900 .
  • Björkqvist, M, Wild, EJ, Thiele, J, Silvestroni, A, Andre, R, Lahiri, N et al.. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 2008;205 (8):1869-77. doi: 10.1084/jem.20080178. PubMed PMID:18625748 PubMed Central PMC2525598.
  • Semaka, A, Warby, S, Leavitt, BR, Hayden, MR. Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov. Disord. 2008;23 (12):1794-5; author reply 1793. doi: 10.1002/mds.21820. PubMed PMID:18548612 .
  • Björkqvist, M, Leavitt, BR, Nielsen, JE, Landwehrmeyer, B, Ecker, D, Mulder, H et al.. Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Mov. Disord. 2007;22 (13):1952-4. doi: 10.1002/mds.21447. PubMed PMID:17722045 .
  • Wong, D, Dwinnel, M, Schulzer, M, Nimmo, M, Leavitt, BR, Spacey, SD et al.. Ataxia and the role of antigliadin antibodies. Can J Neurol Sci. 2007;34 (2):193-6. . PubMed PMID:17598597 .
  • Dalrymple, A, Wild, EJ, Joubert, R, Sathasivam, K, Björkqvist, M, Petersén, A et al.. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 2007;6 (7):2833-40. doi: 10.1021/pr0700753. PubMed PMID:17552550 .
  • Kuhn, A, Goldstein, DR, Hodges, A, Strand, AD, Sengstag, T, Kooperberg, C et al.. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum. Mol. Genet. 2007;16 (15):1845-61. doi: 10.1093/hmg/ddm133. PubMed PMID:17519223 .
  • Butland, SL, Devon, RS, Huang, Y, Mead, CL, Meynert, AM, Neal, SJ et al.. CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics. 2007;8 :126. doi: 10.1186/1471-2164-8-126. PubMed PMID:17519034 PubMed Central PMC1896166.
  • Van Raamsdonk, JM, Murphy, Z, Selva, DM, Hamidizadeh, R, Pearson, J, Petersén, A et al.. Testicular degeneration in Huntington disease. Neurobiol. Dis. 2007;26 (3):512-20. doi: 10.1016/j.nbd.2007.01.006. PubMed PMID:17433700 .
  • Van Raamsdonk, JM, Metzler, M, Slow, E, Pearson, J, Schwab, C, Carroll, J et al.. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiol. Dis. 2007;26 (1):189-200. doi: 10.1016/j.nbd.2006.12.010. PubMed PMID:17276692 .
  • Van Raamsdonk, JM, Pearson, J, Murphy, Z, Hayden, MR, Leavitt, BR. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. BMC Neurosci. 2006;7 :80. doi: 10.1186/1471-2202-7-80. PubMed PMID:17147801 PubMed Central PMC1762017.
  • Zhang, Y, Leavitt, BR, van Raamsdonk, JM, Dragatsis, I, Goldowitz, D, MacDonald, ME et al.. Huntingtin inhibits caspase-3 activation. EMBO J. 2006;25 (24):5896-906. doi: 10.1038/sj.emboj.7601445. PubMed PMID:17124493 PubMed Central PMC1698892.
  • Leavitt, BR, Hayden, MR. Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease?. Nat Clin Pract Neurol. 2006;2 (10):536-7. doi: 10.1038/ncpneuro0299. PubMed PMID:16990826 .
  • Mackenzie, IR, Butland, SL, Devon, RS, Dwosh, E, Feldman, H, Lindholm, C et al.. Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. BMC Neurol. 2006;6 :32. doi: 10.1186/1471-2377-6-32. PubMed PMID:16945149 PubMed Central PMC1570137.
  • Björkqvist, M, Petersén, A, Nielsen, J, Ecker, D, Mulder, H, Hayden, MR et al.. Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clin. Genet. 2006;70 (1):78-9. doi: 10.1111/j.1399-0004.2006.00636.x. PubMed PMID:16813610 .
  • Graham, RK, Deng, Y, Slow, EJ, Haigh, B, Bissada, N, Lu, G et al.. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125 (6):1179-91. doi: 10.1016/j.cell.2006.04.026. PubMed PMID:16777606 .
  • Devon, RS, Orban, PC, Gerrow, K, Barbieri, MA, Schwab, C, Cao, LP et al.. Als2-deficient mice exhibit disturbances in endosome trafficking associated with motor behavioral abnormalities. Proc. Natl. Acad. Sci. U.S.A. 2006;103 (25):9595-600. doi: 10.1073/pnas.0510197103. PubMed PMID:16769894 PubMed Central PMC1480452.
Search PubMed